title: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
abstract: This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3 mg/m(2) (days 1, 4, 8, 11), lenalidomide 15 to 25 mg (days 1-14), and dexamethasone 40 or 20 mg (days 1, 2, 4, 5, 8, 9, 11, 12). Responding patients proceeded to maintenance or transplantation. Phase 2 dosing was determined to be bortezomib 1.3 mg/m(2), lenalidomide 25 mg, and dexamethasone 20 mg. Most common toxicities included sensory neuropathy (80%) and fatigue (64%), with only 27%/2% and 32%/3% grade 2/3, respectively. In addition, 32% reported neuropathic pain (11%/3%, grade 2/3). Grade 3/4 hematologic toxicities included lymphopenia (14%), neutropenia (9%), and thrombocytopenia (6%). Thrombosis was rare (6% overall), and no treatment-related mortality was observed. Rate of partial response was 100% in both the phase 2 population and overall, with 74% and 67% each achieving very good partial response or better. Twenty-eight patients (42%) proceeded to undergo transplantation. With median follow-up of 21 months, estimated 18-month progression-free and overall survival for the combination treatment with/without transplantation were 75% and 97%, respectively. Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
authors.forename: Paul G
authors.initials: PG
authors.lastname: Richardson
authors.forename: Edie
authors.initials: E
authors.lastname: Weller
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.forename: Andrzej J
authors.initials: AJ
authors.lastname: Jakubowiak
authors.forename: Sundar
authors.initials: S
authors.lastname: Jagannath
authors.forename: Noopur S
authors.initials: NS
authors.lastname: Raje
authors.forename: David E
authors.initials: DE
authors.lastname: Avigan
authors.forename: Wanling
authors.initials: W
authors.lastname: Xie
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
authors.forename: Robert L
authors.initials: RL
authors.lastname: Schlossman
authors.forename: Amitabha
authors.initials: A
authors.lastname: Mazumder
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
authors.forename: David H
authors.initials: DH
authors.lastname: Vesole
authors.forename: Robin
authors.initials: R
authors.lastname: Joyce
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Kaufman
authors.forename: Deborah
authors.initials: D
authors.lastname: Doss
authors.forename: Diane L
authors.initials: DL
authors.lastname: Warren
authors.forename: Laura E
authors.initials: LE
authors.lastname: Lunde
authors.forename: Sarah
authors.initials: S
authors.lastname: Kaster
authors.forename: Carol
authors.initials: C
authors.lastname: Delaney
authors.forename: Teru
authors.initials: T
authors.lastname: Hideshima
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Mitsiades
authors.forename: Robert
authors.initials: R
authors.lastname: Knight
authors.forename: Dixie-Lee
authors.initials: DL
authors.lastname: Esseltine
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005221:Fatigue / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D010146:Pain / Q000139:chemically induced; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012678:Sensation Disorders / Q000139:chemically induced; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide
references.citation: Br J Haematol. 1998 Sep;102(5):1115-23
references.pmid: 9753033
references.citation: Br J Haematol. 2008 Oct;143(2):222-9
references.pmid: 18713253
references.citation: Blood. 2008 Mar 1;111(5):2516-20
references.pmid: 17975015
references.citation: N Engl J Med. 2008 Aug 28;359(9):906-17
references.pmid: 18753647
references.citation: Blood. 2007 Apr 15;109(8):3489-95
references.pmid: 17209057
references.citation: Cancer Res. 2001 Apr 1;61(7):3071-6
references.pmid: 11306489
references.citation: Cancer. 2008 Apr 1;112(7):1522-8
references.pmid: 18278812
references.citation: Haematologica. 2006 Nov;91(11):1498-505
references.pmid: 17043025
references.citation: Leukemia. 2009 Mar;23(3):449-56
references.pmid: 19005483
references.citation: Haematologica. 2007 Oct;92(10):1399-406
references.pmid: 18024376
references.citation: Leuk Lymphoma. 2007 Dec;48(12):2330-7
references.pmid: 18067007
references.citation: Blood. 2009 Oct 8;114(15):3139-46
references.pmid: 19638622
references.citation: Blood. 2002 Jun 15;99(12):4525-30
references.pmid: 12036884
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5713-9
references.pmid: 19786667
references.citation: Blood. 2011 Jul 21;118(3):535-43
references.pmid: 21596852
references.citation: Hematology. 2010 Apr;15(2):70-3
references.pmid: 20423566
references.citation: Leukemia. 2009 Jun;23(6):1152-7
references.pmid: 19225533
references.citation: Mayo Clin Proc. 2007 Oct;82(10):1179-84
references.pmid: 17908524
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: N Engl J Med. 2007 Nov 22;357(21):2123-32
references.pmid: 18032762
references.citation: N Engl J Med. 2007 Nov 22;357(21):2133-42
references.pmid: 18032763
references.citation: Cancer. 2006 May 1;106(9):1958-66
references.pmid: 16565956
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Blood. 2005 Dec 15;106(13):4050-3
references.pmid: 16118317
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9
references.pmid: 12391322
references.citation: Br J Haematol. 2009 Mar;144(6):895-903
references.pmid: 19170677
references.citation: Blood. 2006 Jul 1;108(1):403; author reply 404
references.pmid: 16790586
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3518-25
references.pmid: 19528374
references.citation: Lancet Oncol. 2010 Jan;11(1):29-37
references.pmid: 19853510
references.citation: Leukemia. 2006 Sep;20(9):1467-73
references.pmid: 16855634